Klingenstein Fields & Co. LLC raised its holdings in Celgene Corporation (NASDAQ:CELG) by 7.2% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 180,663 shares of the biopharmaceutical company’s stock after acquiring an additional 12,166 shares during the quarter. Klingenstein Fields & Co. LLC’s holdings in Celgene Corporation were worth $23,463,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in CELG. Harbour Capital Advisors LLC grew its position in Celgene Corporation by 12,913.6% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,587,271 shares of the biopharmaceutical company’s stock valued at $12,222,000 after acquiring an additional 1,575,074 shares during the last quarter. Investec Asset Management LTD bought a new position in shares of Celgene Corporation during the 1st quarter worth $194,490,000. Clearbridge Investments LLC grew its position in shares of Celgene Corporation by 24.1% during the 1st quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock worth $572,617,000 after buying an additional 892,392 shares in the last quarter. State Street Corp grew its position in shares of Celgene Corporation by 2.3% during the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after buying an additional 723,844 shares in the last quarter. Finally, Pioneer Investment Management Inc. grew its position in shares of Celgene Corporation by 15.7% during the 1st quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after buying an additional 710,584 shares in the last quarter. 79.33% of the stock is currently owned by institutional investors.

Celgene Corporation (CELG) opened at 144.24 on Thursday. The stock has a 50 day moving average price of $135.45 and a 200 day moving average price of $127.81. The stock has a market capitalization of $112.85 billion, a PE ratio of 44.67 and a beta of 1.89. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $144.45.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same period in the previous year, the business earned $1.44 EPS. The business’s quarterly revenue was up 18.7% on a year-over-year basis. Equities analysts forecast that Celgene Corporation will post $7.32 EPS for the current year.

In other Celgene Corporation news, Director James J. Loughlin sold 18,500 shares of the company’s stock in a transaction that occurred on Monday, June 26th. The stock was sold at an average price of $133.57, for a total transaction of $2,471,045.00. Following the completion of the sale, the director now directly owns 32,877 shares of the company’s stock, valued at approximately $4,391,380.89. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now directly owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The disclosure for this sale can be found here. Insiders sold a total of 63,006 shares of company stock valued at $8,490,806 over the last three months. Company insiders own 0.95% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Celgene Corporation (CELG) Shares Bought by Klingenstein Fields & Co. LLC” was published by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/21/celgene-corporation-celg-shares-bought-by-klingenstein-fields-co-llc.html.

A number of equities analysts have recently issued reports on CELG shares. Oppenheimer Holdings, Inc. set a $148.00 price target on Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, June 8th. Cann reissued a “buy” rating on shares of Celgene Corporation in a research report on Wednesday, June 7th. Canaccord Genuity set a $156.00 price target on Celgene Corporation and gave the stock a “buy” rating in a research report on Tuesday, June 6th. Mizuho increased their price target on Celgene Corporation from $130.00 to $134.00 and gave the stock a “buy” rating in a research report on Thursday, June 1st. Finally, BTIG Research reissued a “buy” rating and set a $138.00 price target on shares of Celgene Corporation in a research report on Wednesday, May 24th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $149.34.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.